Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia

Table 3 Cost-effectiveness of antibiotics for treatment of pneumonia patients

Treatment strategy	Total cost (USD)	Incremental cost (USD)	Total LY	LY saved^a	ICER per LY saved
Vancomycin	16,346		9.84
Teicoplanin	12,487	− 3858	10.80	0.96	Dominant
Linezolid	19,230	2884	11.16	1.32	2185

USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio
^aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin

ISSN: 2047-2994